Abstract

BackgroundOne primary goal of transcriptomic studies is identifying gene expression patterns correlating with disease progression. This is usually achieved by considering transcripts that independently pass an arbitrary threshold (e.g. p<0.05). In diseases involving severe perturbations of multiple molecular systems, such as Alzheimer’s disease (AD), this univariate approach often results in a large list of seemingly unrelated transcripts. We utilised a powerful multivariate clustering approach to identify clusters of RNA biomarkers strongly associated with markers of AD progression. We discuss the value of considering pairs of transcripts which, in contrast to individual transcripts, helps avoid natural human transcriptome variation that can overshadow disease-related changes.Methodology/Principal FindingsWe re-analysed a dataset of hippocampal transcript levels in nine controls and 22 patients with varying degrees of AD. A large-scale clustering approach determined groups of transcript probe sets that correlate strongly with measures of AD progression, including both clinical and neuropathological measures and quantifiers of the characteristic transcriptome shift from control to severe AD. This enabled identification of restricted groups of highly correlated probe sets from an initial list of 1,372 previously published by our group. We repeated this analysis on an expanded dataset that included all pair-wise combinations of the 1,372 probe sets. As clustering of this massive dataset is unfeasible using standard computational tools, we adapted and re-implemented a clustering algorithm that uses external memory algorithmic approach. This identified various pairs that strongly correlated with markers of AD progression and highlighted important biological pathways potentially involved in AD pathogenesis.Conclusions/SignificanceOur analyses demonstrate that, although there exists a relatively large molecular signature of AD progression, only a small number of transcripts recurrently cluster with different markers of AD progression. Furthermore, considering the relationship between two transcripts can highlight important biological relationships that are missed when considering either transcript in isolation.

Highlights

  • Alzheimer’s disease (AD) is an irreversible brain disease that begins with mild memory impairment but eventually progresses to severe brain dysfunction and dementia

  • Probe sets are highlighted for several reasons, including having a strong correlation with one or more progression markers or appearing in a metafeature with a probe set for another gene which has a potential role in AD or in other brain disease

  • We identified metafeatures comprising probe sets targeting genes previously studied in the context of AD (VSNL1, PPP2CA, CYP3A4) and genes highlighted by the analysis in Gomez Ravetti et al [5] (PTEN, MAPK1, COX6A1, GABRQ, FCAR, FZD5, PIP5K1C, SHANK2, Carnitine palmitoyltransferase 2 (CPT2))

Read more

Summary

Introduction

Alzheimer’s disease (AD) is an irreversible brain disease that begins with mild memory impairment but eventually progresses to severe brain dysfunction and dementia. In 2004, Blalock and colleagues [3] made an important contribution towards finding a set of molecular biomarkers that correlate with the progression of AD in one region of the brain. Using microarray technology, they assessed RNA transcript levels in post-mortem hippocampal tissue from 9 controls and 22 patients with varying degrees of AD severity. One primary goal of transcriptomic studies is identifying gene expression patterns correlating with disease progression. This is usually achieved by considering transcripts that independently pass an arbitrary threshold (e.g. p,0.05). We discuss the value of considering pairs of transcripts which, in contrast to individual transcripts, helps avoid natural human transcriptome variation that can overshadow disease-related changes

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.